Recurrent fallopian tube carcinoma Trials in Mentor, United States
Conditions / Recurrent fallopian tube carcinoma / Mentor, United States
Research into Recurrent fallopian tube carcinoma spans multiple therapeutic approaches and trial phases.
20 total trials for this combination
Showing top 10 of 20 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05554328 | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | RECRUITING | — |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | COMPLETED | — |
| NCT01372787 | Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | UNKNOWN | — |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01081262 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02446600 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | UNKNOWN | PHASE3 |
| NCT02315430 | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | COMPLETED | PHASE2 |